Universidad Complutense de Madrid
Madrid, 28040, Spain
NCT Number: NCT00804414
Evaluation of efficacy and safety of SBG vs placebo in the treatment of chronic diabetic foot ulcers.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Madrid, 28040, Spain
The objective of this study is to evaluate efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on chronic diabetic foot ulcers.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Solution for topical use
Solutin for topical use
Time frame: Maximum 12 weeks
Biotec Pharmacon ASA
Industry
A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Soluble Beta-1,3/1,6-glucan (SBG) in Chronic Foot Ulcers in Patients With Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial DetailsNCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial Details